Fresenius Medical Care AG FME

European equities traded in the US as American depositary receipts were lower on Tuesday morning, de

FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced refinements to its China commercial strategy to support long-term growth and strengthen its market position through a more localized portfolio, increased commercialization of locally relevant innovation and a focused go-to-market approach.

The U.S. Food and Drug Administration (FDA) on Tuesday issued a warning letter to Fresenius Medical Care AG & Co. KGaA’s Fresenius USA Manufacturing following a March 2026 inspection at its Ogden, Utah production facility. In a letter to the...

Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.

Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, today announced the publication of a large international study reporting that hemodiafiltration (HDF) was associated with lower relative risk of death from any cause compared with conventional high-flux hemodialysis.

U.S. referral execution gap offset by strong margin expansion and transformation savings.

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest the market may be pricing it on the cheap side rather than as a fully valued turnaround story. The share price has declined 29.6% over five years, which points to a company that has struggled to create positive long term returns for shareholders. Recent progress in patient care technology and leadership changes can support sentiment...

Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer of the Care Delivery segment, reshaping leadership oversight of its global clinic operations. See our latest analysis for Fresenius Medical Care. The leadership change at Fresenius Medical Care comes just after a Q2 report where solid operating income and organic growth were followed by a sharp 1 day share price decline of...

Moby summary of Fresenius Medical Care AG & Co. KGaA's Q2 2026 earnings call

FMS delivers 23% operating income growth and margin expansion, while navigating US referral headwinds and TDAPA roll-off.

Fresenius Medical Care (NYSE:FMS) shares fell 8. 0% to €41.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in t

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to...

- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America - - Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center - DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq:

German health care group Fresenius on Monday reaffirmed its annual earnings outlook, maintaining its forecast for adjusted earnings growth this year. Excluding its stakes in Fresenius Medical Care and Vitrea, the company continues to expect core earnings per share to grow by 5% to 10% in fiscal 2026.